Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France
- 169 Downloads
Diffuse WHO grade II and III gliomas (DGII/IIIG) are rare tumors, with few specific epidemiological studies. We aimed at describing the geographical distribution of a homogeneous series of histologically confirmed DGII/IIIG, over a four-year period (2006–2009), at a national level. The methodology is based on a multidisciplinary national network already established by the French Brain Tumor DataBase and data collected directly from every neuropathology department. Personal home addresses were collected for confirmed cases. For each region, the incidence of DGII/IIIG was analyzed and standardized on the age and sex distribution of the French population. The number of patients with newly diagnosed, histologically confirmed DGII/IIIG was 4,790. The overall crude rate was 19.4/106. To enable international comparisons, standardized rates were calculated as follows: 19.8/106, 18.8/106 and 16.0/106 (reference population, Europe, US and world, respectively). The geographical distribution by region showed significant differences, with higher incidence rates in Northeast and central parts of France. This work is the first studying the geographical distribution of a pure series of DGII/IIIG at a national level. It demonstrates significant heterogeneity in the distribution, and raises the question of the role of environmental and/or genetic risk(s) factor(s) for DGII/IIIG.
KeywordsBrain tumor Neurooncology Glioma Epidemiology
The authors wish to thank all pathologists, neurosurgeons and other stakeholders, for their help and input with this work (see the list in supplementary materials), and Bénédicte Clément, scientific translator, for valuable translation work. This work was conducted with the financial support in the form of grants from the Ligue Nationale Contre le Cancer, Association des Neuro-Oncologues d’Expression Française, Société Française de Neurochirurgie, Associations pour la Recherche sur les Tumeurs Cérébrales (ARTC and ARTC Sud), Roche Laboratory, Sophysa Laboratory, Département de l’Hérault, and Groupe de Neuro-Oncologie du Languedoc Roussillon.
Conflict of interest